NASDAQ:BTAI BioXcel Therapeutics Q3 2025 Earnings Report $2.33 +0.07 (+3.10%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$2.34 +0.00 (+0.21%) As of 10/24/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast BioXcel Therapeutics EPS ResultsActual EPSN/AConsensus EPS -$1.54Beat/MissN/AOne Year Ago EPSN/ABioXcel Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$0.20 millionBeat/MissN/AYoY Revenue GrowthN/ABioXcel Therapeutics Announcement DetailsQuarterQ3 2025Date11/13/2025TimeBefore Market OpensConference Call DateThursday, November 13, 2025Conference Call Time8:00AM ETConference Call ResourcesEarnings HistoryCompany Profile BioXcel Therapeutics Earnings HeadlinesHalper Sadeh LLC Encourages BioXcel Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their RightsOctober 24 at 11:38 AM | businesswire.comBioXcel Announces Positive SERENITY At Home Study ResultsOctober 16, 2025 | theglobeandmail.comTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.October 25 at 2:00 AM | Porter & Company (Ad)BioXcel Therapeutics Rings the Closing BellOctober 14, 2025 | nasdaq.comBioXcel announces results from correlation study from SERENITY At-Home trialOctober 14, 2025 | msn.comBioXcel Therapeutics Announces Positive Results from Correlation Study Supporting SERENITY At-Home Exploratory Efficacy OutcomesOctober 14, 2025 | globenewswire.comSee More BioXcel Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like BioXcel Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioXcel Therapeutics and other key companies, straight to your email. Email Address About BioXcel TherapeuticsBioXcel Therapeutics (NASDAQ:BTAI) is a biopharmaceutical company leveraging an AI-driven drug development platform to identify and advance novel or repurposed therapies in neuroscience and immunology. The proprietary BioXcel AI engine analyzes preclinical and clinical data to reveal new therapeutic applications for existing small molecules and biologics, aiming to streamline development timelines and improve patient outcomes. BioXcel’s commercial portfolio includes two FDA-approved therapies. IGALMI® (dexmedetomidine) is indicated for the acute treatment of agitation in schizophrenia or bipolar I disorder, offering a noninvasive, sublingual delivery option. ZYESAMI® (aviptadil) is authorized for the treatment of acute respiratory distress syndrome, including in patients with critical COVID-19–related respiratory failure, representing the company’s expansion into critical care medicine. In addition to its marketed products, BioXcel maintains a diversified pipeline of clinical and preclinical programs targeting neuropsychiatric and immuno-oncology indications. The company collaborates with academic institutions and strategic partners to further validate its AI-identified assets and explore new indications, underpinning its strategy to deliver differentiated treatments across multiple therapeutic areas. Founded in 2017 and headquartered in New Haven, Connecticut, BioXcel Therapeutics completed its public listing in 2019. The company currently serves the U.S. market and is evaluating opportunities for global expansion. Under the leadership of President and CEO Vimal Mehta, M.D., Ph.D., BioXcel is focused on growing its commercial footprint and advancing its AI-enabled pipeline toward key regulatory milestones.View BioXcel Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Freeport-McMoRan Posts Strong Earnings Despite Indonesia ShutdownTesla’s Earnings Review: Does the Juice Justify the Squeeze?Fal.Con Europe Could Be CrowdStrike’s Early Earnings CatalystLogitech Eyes Breakout Before Earnings—Citigroup Sees 30% UpsideLouis Vuitton Earnings Show Luxury Bull Market Isn’t Done YetGoldman Sachs Earnings Tell: Markets Seem OkayWhy Congress Is Buying Intuitive Surgical Ahead of Earnings Upcoming Earnings Cadence Design Systems (10/27/2025)NXP Semiconductors (10/27/2025)Welltower (10/27/2025)Waste Management (10/27/2025)Booking (10/28/2025)Electronic Arts (10/28/2025)Mondelez International (10/28/2025)PayPal (10/28/2025)Regeneron Pharmaceuticals (10/28/2025)American Tower (10/28/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
